Cocrystal Pharma, Inc. (COCP) vs Estrella Immunopharma, Inc. (ESLA)

A side-by-side comparison of Cocrystal Pharma, Inc. and Estrella Immunopharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — COCP vs ESLA

growth of $100 · dividends reinvested · last 5y
COCP -91.5% (-38.9%/yr)ESLA -95.5% (-46.2%/yr)COCP compounded faster over this window
050100150Start $10020222023202420252026$8$5
COCP ESLA

COCP vs ESLA: by the numbers

  • •ESLA is the larger company ($18M vs $15M market cap).
  • •Both run net losses; ESLA's is the smaller (0.00% vs -3011.52% net margin).

Metrics side by side

Valuation

MetricCOCPESLA
P/S ratio46.38N/A
P/B ratio14.66N/A

Profitability

MetricCOCPESLA
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin-3011.52%0.00%
ROE-951.92%N/A
ROIC-497.29%N/A

Growth (annualized)

MetricCOCPESLA
Revenue CAGR (5Y)91.55%N/A
Total return CAGR (5Y)-37.50%-46.34%

Frequently asked

How have COCP and ESLA total returns compared?
Over the past 5 years, COCP delivered -37.50% and ESLA delivered -46.34% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.